How to manage relapsed/refractory MCL - new agents and unmet needs
How can MRD and disease be assessed in routine practice?
Technology guiding future directions in CLL
Overcoming the shortfalls of ibrutinib with fludarabine in CLL patientss
The challenges associated with managing multiple myeloma patients on immunotherapy
Ignacio Melero Bermejo